Ajooni Biotech Limited (AJOONI) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Ajooni Biotech Limited stock ₹4.27, price ₹2.83, upside +50.9%, quality 40 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range ₹2.83 – ₹14.43 · fair‑value band ₹3.20 – ₹5.33 · the ₹2.83 price screens below the ₹4.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Ajooni Biotech in your weekly email
Every Wednesday you see whether Ajooni Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ajooni Biotech Limited manufactures and sells cattle feed in India. Its portfolio includes cattle feed chips, camel and pig feed, cotton oil cakes, mustard oil cakes, and feed supplements. The company was incorporated in 2010 and is based in Mohali, India.
Stock analysis
Ajooni Biotech Limited (AJOONI) currently trades at ₹2.83, while our model-based Fair Value estimate is ₹4.27, implying the stock looks roughly 34% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹11.32 per share, and 10 of the 14 models we run sit above the ₹2.83 price.
Bear case: the Economic Profit group reads lowest at ₹2.56, and 4 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹3.20 (bear) to ₹5.33 (bull), the price of ₹2.83 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Ajooni Biotech Limited reported revenue of ₹1.8B in FY2026 versus ₹740M in FY2022, a compound +25.3%/yr. Reported net income was ₹43.2M in FY2026, compounding +42.5%/yr from FY2022.
Key figures
Market cap ₹487M (≈ $5.2M) Micro · P/E ratio 11.3 · P/S ratio 0.23 · EPS (TTM) ₹0.2500 · Net margin 1.9% · Return on equity 4.4% · Return on assets (EBIT) 3.8% (5-year average) · Operating margin 1.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 3% fair-value upside, at 51%, AJOONI screens cheaper than that median.
Fair Value models
Bear₹3.20Fair Value ₹4.27Bull₹5.33
Price ₹2.83 · Upside +50.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹0.1548 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+59.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.0%
Start year 2021 (pandemic). Over 10 years: +30.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+30.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+30.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.30.7% vs 25.4%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 2%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 660 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+50.9% · Top 25%
Profitability
Return on equity (12 months)4.4% · Below median
Return on assets3.6% · Below median
Net margin (12 months)1.9% · Below median
Operating margin (12 months)1.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)99.8% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Ajooni Biotech Limited (AJOONI) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of ₹4.27 versus a price of ₹2.83, about +51% upside (undervalued).
What is the fair value of AJOONI?
Our model-based fair value for Ajooni Biotech Limited is ₹4.27 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹2.83.
What is the quality score of AJOONI?
Ajooni Biotech Limited has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ajooni Biotech Limited (AJOONI)?
Our model-based price target is the fair value of ₹4.27 (as of Nov 10, 2026) from 14 valuation models. Cautious scenario ₹3.20, optimistic scenario ₹5.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Ajooni Biotech Limited stock forecast for 2026?
Our models put fair value at ₹4.27, about +51% upside versus a price of ₹2.83 (undervalued). Cautious scenario ₹3.20, optimistic scenario ₹5.33. The calculation is refreshed regularly with new filings.
What is the revenue of Ajooni Biotech Limited (AJOONI)?
Ajooni Biotech Limited reported trailing-twelve-month revenue of about ₹2.1B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Ajooni Biotech Limited (AJOONI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ajooni Biotech Limited it is ₹4.27 per share (as of Nov 10, 2026), against a price of ₹2.83. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Ajooni Biotech Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AJOONI trades below its calculated fair value: price ₹2.83, fair value ₹4.27, a gap of about +51% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AJOONI?
No. The price is what the market pays today (₹2.83); the fair value is what the company's own numbers justify (₹4.27). For Ajooni Biotech Limited the two are ₹1.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ajooni Biotech Limited worth?
The market values Ajooni Biotech Limited at about ₹487M (market capitalisation, as of Nov 10, 2026). Per share that is ₹2.83; our models calculate a fair value of ₹4.27 per share.
What do the bullish and bearish scenarios say about AJOONI?
Our models span a range for Ajooni Biotech Limited: cautious scenario ₹3.20, base ₹4.27, optimistic ₹5.33 per share (as of Nov 10, 2026, price ₹2.83). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AJOONI?
Ajooni Biotech Limited trades at a price-to-earnings ratio of 11.3 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹4.27 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.2, EV/EBITDA 6.3.
How solid is the balance sheet of Ajooni Biotech Limited (AJOONI)?
Balance-sheet figures for Ajooni Biotech Limited (as of Nov 10, 2026): return on equity 4.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is AJOONI from its 52-week high?
Ajooni Biotech Limited trades at ₹2.83, about 45% below its 52-week high of ₹5.15 and at the low of ₹2.83 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹4.27 is for.
Which stocks are comparable to Ajooni Biotech Limited?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ajooni Biotech Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹2.83, calculated fair value ₹4.27 (+51%), Quality Score 40/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AJOONI calculated?
We run Ajooni Biotech Limited through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹4.27 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Ajooni Biotech Limited currently trades 34% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ajooni Biotech Limited (AJOONI)?
The closing price on Nov 11, 2026 was ₹2.83. Our model-based fair value is ₹4.27, about +51% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ajooni Biotech Limited right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (₹3.20). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Ajooni Biotech Limited (AJOONI) come from?
Earnings per share at Ajooni Biotech Limited grew +20.4 % a year from 2015 to 2026. Broken into its drivers: revenue per share +7.2 %, EBIT margin +3.3 %, tax rate +0.6 %, residual (interest, one-offs) +8.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ajooni Biotech Limited
How large is the market capitalisation of Ajooni Biotech Limited (AJOONI)?
The market capitalisation of Ajooni Biotech Limited is ₹487M (≈ $5.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ajooni Biotech Limited (AJOONI)?
The price-to-sales ratio of Ajooni Biotech Limited is 0.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ajooni Biotech Limited (AJOONI)?
Earnings per share at Ajooni Biotech Limited are ₹0.2500 (price ÷ EPS = P/E 11.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ajooni Biotech Limited (AJOONI)?
The net margin of Ajooni Biotech Limited is 1.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ajooni Biotech Limited (AJOONI)?
The return on equity (ROE) of Ajooni Biotech Limited is 4.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ajooni Biotech Limited (AJOONI)?
On an EBIT basis the return on assets of Ajooni Biotech Limited is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ajooni Biotech Limited (AJOONI)?
The operating margin of Ajooni Biotech Limited is 1.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ajooni Biotech Limited (AJOONI)?
Revenue at Ajooni Biotech Limited is growing +99.8% versus a year earlier (3y avg +34.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ajooni Biotech Limited (AJOONI)?
Earnings per share at Ajooni Biotech Limited are growing −44.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ajooni Biotech Limited (AJOONI) generate?
The free cash flow of Ajooni Biotech Limited is −₹232M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ajooni Biotech Limited (AJOONI) carry?
The net debt of Ajooni Biotech Limited is ₹173M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ajooni Biotech Limited in the live analysis
One click puts Ajooni Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026